A new way to view CGM data that focuses on patterns, not perfection.
Abstract
This post explores how visualizing glucose data by the hour—rather than by day—can reveal clearer, more supportive insights into blood sugar patterns. By focusing on when changes occur, not just how much, this approach promotes understanding, reduces anxiety, and encourages progress over perfection.
Key Points
Read more: How an Hour-by-Hour View Transforms Time in Range Insights
The 5K@ADA virtual 5K run/walk event is coming soon! Registration is open!
Registration is free.
The 5K@ADA Virtual Challenge will bring together people across the globe as well as ADA attendees to emphasize the need for increased physical activity to help prevent diabetes and diabetes complications. This disease awareness activity provides participants with the opportunity to raise public awareness about the importance of a healthy lifestyle in preventing and controlling diabetes.
The 5K@ADA is sponsored by Novo Nordisk and the American Diabetes Association (ADA). It takes place in conjunction with the ADA annual conference.
I do the walk on the treadmill at the gym. This way I can have my earbuds in, easily track my progress and not have any interruptions.
Upload your race time any time between the race start and end dates.
5K@ADA Virtual Challenge
https://www.ada5k.com/
June 18 - June 22, 2025
Registration is open. Personalized bibs are available 48 hours after signup.
Continue driving change in diabetes by running or walking the 5K@ADA in Chicago or from your home city!
Summary
Eli Lilly’s tirzepatide has shown remarkable potential in reducing the risk of type 2 diabetes by 94% in overweight and obese adults, according to new data from the SURMOUNT-1 study. This breakthrough not only highlights tirzepatide's effectiveness in diabetes prevention but also its significant impact on weight loss.
Key Points
Pharmaceutical leaders Eli Lilly and Novo Nordisk are making significant investments to expand their manufacturing capacities for GLP-1 drugs, which are crucial for diabetes and obesity treatments. Eli Lilly is dedicating an additional $5.3 billion to its Indiana site, aiming to address current drug shortages and enhance production of tirzepatide (marketed as Mounjaro and Zepbound). Concurrently, Novo Nordisk is investing $4.1 billion in its North Carolina facility to boost the production of injectable treatments. These efforts highlight the companies' commitment to meeting the growing global demand for these essential medications and ensuring a stable supply chain.
Key Points
Read more: Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Page 3 of 22
